
Stereotaxis Announces First GenesisX Robotic System Order
ST. LOUIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has received the first order for its latest generation robotic system, GenesisX™.
'We are thrilled to announce the first firm order for GenesisX from a pioneering European hospital,' said David Fischel, Stereotaxis Chairman and CEO. 'Establishing the first GenesisX robotic lab is a critical milestone for us as we advance towards full commercial launch. We look forward to demonstrating the performance and reliability of GenesisX in the demanding clinical environment. GenesisX promises to transform the accessibility of Robotic Magnetic Navigation and is central to our mission of driving broad robotic adoption throughout endovascular surgery.'
GenesisX is the latest advance in endovascular surgical robotics, building upon the established benefits of Robotic Magnetic Navigation while significantly enhancing the accessibility of the technology for healthcare providers. GenesisX utilizes smaller magnets and incorporates magnetic shielding into its structure in place of the shielding otherwise installed in the walls of the operating room. It requires no structural anchoring through the floor and operates using standard 120/230V power outlets. A single fiber is routed from each robot to the system cabinet, which is 80% smaller than previous cabinets and can fit under a table in the operating room. GenesisX is smaller and lighter than any previous generation system, while maintaining the highest standards in speed, responsiveness, and efficient workflow.
GenesisX obtained CE Mark in Europe in 2024 and has been submitted to the FDA for 510(k) clearance in the United States. During 2025, Stereotaxis plans to gain regulatory approvals in Europe and the US for a portfolio of compatible EP and vascular catheters, demonstrate real-world use of GenesisX, enhance compatibility of GenesisX with various x-rays, and prepare supply chain, manufacturing, installation and commercial processes for a full launch.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com
This press release includes statements that may constitute 'forward-looking' statements, usually containing the words 'believe', 'estimate', 'project', 'expect' or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
David L. Fischel
Kimberly Peery
Chief Financial Officer
314-678-6100
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Ferguson Debuts on 2025 Fortune 500 List
Achievement reinforces the company's impact on the North American construction market NEWPORT NEWS, Va., June 10, 2025--(BUSINESS WIRE)--Ferguson Enterprises, Inc. (NYSE: FERG; LSE: FERG) is proud to announce its debut on the 2025 Fortune 500 list, earning the 146th position. This milestone reflects the company's impact on the North American construction industry and reinforces its position as the largest value-added distributor in its $340B residential and non-residential construction markets. The Fortune 500 list, published annually by Fortune magazine, ranks the top 500 U.S. companies by total revenue for their respective fiscal year. Ferguson earned its place on the list with revenues of $29.6B in fiscal year 2024 and after completing a corporate restructure that moved its headquarters to the U.S. in Aug. 2024. "We are honored to join the Fortune 500 list," said CEO Kevin Murphy. "It's a testament to the dedication and hard work of our associates and the strong industry relationships we have fostered with both customers and suppliers. We are proud to serve the specialized trade professionals who rely on us to make their complex projects simple, successful and sustainable." Ferguson holds leading positions in many of the markets it serves. The company's expert associates — combined with a world-class supply chain, value-added solutions and digital tools — drive construction productivity and enable project success. About Ferguson Ferguson (NYSE: FERG; LSE: FERG) is the largest value-added distributor serving the specialized professional in our $340B residential and non-residential North American construction market. We help make our customers' complex projects simple, successful and sustainable by providing expertise and a wide range of products and services from plumbing, HVAC, appliances, and lighting to PVF, water and wastewater solutions, and more. Headquartered in Newport News, Va., Ferguson has sales of $29.6 billion (FY'24) and approximately 35,000 associates in nearly 1,800 locations. For more information, please visit View source version on Contacts Media Inquiries Christine DwyerSenior Director, Communications and Public Relations+1 757 469
Yahoo
35 minutes ago
- Yahoo
LTX, a Broadridge Company, Expands Generative AI Capabilities with BondGPT Intelligence
New functionality proactively delivers actionable intelligence directly into trading and investing workflows at the moment users need these critical insights NEW YORK, June 10, 2025 /PRNewswire/ -- LTX, an AI-powered corporate bond trading platform backed by global Fintech leader Broadridge Financial Solutions Inc. (NYSE:BR), today announced the launch of BondGPT Intelligence, a new capability that integrates powerful generative AI capabilities directly within trading platform workflows. The new functionality intelligently anticipates users' queries based on where they are in the investing and trading workflow, instantly delivering critical answers and empowering users to make informed decisions with speed and confidence. "AI has been a core part of our platform since the beginning. With BondGPT Intelligence, we are enhancing our offering to provide practical value and deeper workflow integration for market participants," said Jim Kwiatkowski, CEO of LTX. "From bond and liquidity discovery to counterparty selection and execution, BondGPT Intelligence integrates practical, sophisticated AI capabilities into every phase of the trading workflow — unlocking the true potential of AI in modern trading." BondGPT Intelligence anticipates clients' needs, proactively putting key insights at traders' fingertips right inside the trading platform. Leveraging the award-winning BondGPT application, BondGPT Intelligence provides immediate access to a wide range of market data and insights, anticipating critical questions in real time, and supporting faster, more informed decision-making without disrupting the trading workflow. Building on its pioneering use of generative AI, LTX continues to transform the fixed income trading experience by proactively delivering actionable intelligence directly into clients' workflows at the moment users need these critical insights. This new capability meets the growing demand to leverage generative AI to enhance productivity and simplify workflows without requiring users to access another system. The launch of BondGPT Intelligence follows the recent announcement of a patent being granted for methods and systems behind BondGPT including the large language model (LLM) orchestration of machine learning agents. These milestones build on LTX's legacy of harnessing advanced AI technology and reinforce Broadridge's overall commitment to advancing intelligent trading solutions. For more information about BondGPT Intelligence, please visit About LTX LTX is an electronic trading platform that enables corporate bond market participants to trade smarter, combining powerful artificial intelligence with patented, innovative e-trading protocols to improve liquidity, efficiency, and execution. LTX is a division of Broadridge Business Process Outsourcing LLC, the broker-dealer subsidiary of Broadridge Financial Solutions. About Broadridge Broadridge Financial Solutions (NYSE: BR) is a global technology leader with the trusted expertise and transformative technology to help clients and the financial services industry operate, innovate, and grow. We power investing, governance, and communications for our clients – driving operational resiliency, elevating business performance, and transforming investor experiences. Our technology and operations platforms process and generate over 7 billion communications per year and underpin the daily trading of more than $10 trillion of securities globally. A certified Great Place to Work®, Broadridge is part of the S&P 500® Index, employing over 14,000 associates in 21 countries. For more information about us, please visit Broadridge Contacts: Investor Relationsbroadridgeir@ Media View original content to download multimedia: SOURCE Broadridge Financial Solutions, Inc. Sign in to access your portfolio
Yahoo
36 minutes ago
- Yahoo
Pharvaris Announces Annual Meeting of Shareholders
ZUG, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 27, 2025, at 16:00 CEST (10:00 a.m. EDT). All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are or will be made available in the 'Investors' section of Pharvaris' website under 'Events & Presentations'. The documents will also be made available on the SEC's website at Shareholders who wish to attend the meeting should register as described in the notice and agenda for the annual general meeting. About PharvarisPharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit CONTACT: Contact Maggie Beller Executive Director, Head of Corporate and Investor Communications